Tyme to Present at Biotech Showcase™ 2018

NEW YORK, Dec. 13, 2017 -- Tyme Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that management will present a company overview at the Biotech Showcase™ 2018, to be held Jan. 8-10, 2018.

Biotech Showcase 2018
Location: San Francisco, Calif.
Presentation date / time: Wednesday, Jan. 10, 2018, 4:30 p.m. PST

About Tyme

Tyme Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. Tyme’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and the Company is preparing to initiate an additional Phase II clinical trial in pancreatic cancer.

For more information about Tyme, visit www.tymeinc.com.

Contacts

Tyme Inc.
Jonathan Eckard
Chief Scientific Affairs Officer
[email protected]

ICR Healthcare
Investors
Stephanie Carrington
[email protected]
646-277-1282

6 Degrees
Media
Sarah Hall
[email protected]
215-313-5638